KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Asset Writedowns and Impairment: 2009-2024

Historic Asset Writedowns and Impairment for Biomarin Pharmaceutical (BMRN) over the last 8 years, with Dec 2024 value amounting to $19.9 million.

  • Biomarin Pharmaceutical's Asset Writedowns and Impairment was N/A to $3.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $48.8 million, marking a year-over-year change of. This contributed to the annual value of $19.9 million for FY2024, which is 48.48% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Asset Writedowns and Impairment stood at $19.9 million for FY2024, which was down 48.48% from $38.6 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Asset Writedowns and Impairment ranged from a high of $75.6 million in FY2020 and a low of $19.9 million during FY2024.
  • Moreover, its 2-year median value for Asset Writedowns and Impairment was $29.2 million (2023), whereas its average is $29.2 million.
  • Data for Biomarin Pharmaceutical's Asset Writedowns and Impairment shows a maximum YoY tumbled of 48.48% (in 2024) over the last 5 years.
  • Over the past 3 years, Biomarin Pharmaceutical's Asset Writedowns and Impairment (Yearly) stood at $75.6 million in 2020, then reached $38.6 million in 2023, then slumped by 48.48% to $19.9 million in 2024.